Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 4Breast Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Stomach Neoplasms 2Prostatic Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Pleural Effusion, Malignant 1Neoplasms, Plasma Cell 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Sirolimus 6Everolimus 5saracatinib 1nintedanib 1Urination 1Sugars 1Simvastatin 1Resveratrol 1Octreotide 1Letrozole 1Imatinib Mesylate 1Hydroxychloroquine 1Glutamine 1Doxycycline 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphangioleiomyomatosis × saracatinib × Clear all
NCT02116712 2016-11-30

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Baylor College of Medicine

Phase 1 Completed
9 enrolled

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡